KED
What is it?
A three-amino-acid research peptide identified by its sequence abbreviation KED. It has been investigated alongside EDR in experimental models of neurodegeneration.
Identity / background source ↗
Research context
A tripeptide research entry connected to experimental neurodegeneration work. No human benefit is inferred from mouse-model findings.
- Working classification
- Short peptide research
- Research collection
- Neuropeptide research · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —Not assessed
- Study methods
- —Not assessed
- Independent replication
- —Not assessed
- Source access
- —See linked publication and review scope
- Safety evidence
- —Not assessed
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Linked sources
Explore the research map and unresolved leads ↗
Neuroprotective Effects of Tripeptides—Epigenetic Regulators in Mouse Model of Alzheimer’s Disease
Author list available on linked original paper · Pharmaceuticals 14(6):515
Investigates EDR and KED in an experimental Alzheimer’s model, including dendritic-spine and neuroplasticity measures. Animal-model findings do not establish human benefit.
- Population / setting
- 5xFAD mouse model and neuronal research
- What was checked
- Source scope and bibliographic record checked; underlying experiments require individual appraisal.
Limitations & review scope
- Animal disease model, not a healthy-person or clinical trial.
- No effect size is entered without complete methods and endpoint review.
Source checked 2026-09-27. This is a source-linked record, not a completed evidence review.
Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease
Author list available on linked original paper · International Journal of Molecular Sciences 23(8):4259
Develops hypotheses connecting short peptides with gene regulation and neurodegenerative processes. Hypotheses are retained as mechanistic proposals, not clinical conclusions.
- Population / setting
- Review of earlier research
- What was checked
- Source scope and bibliographic record checked; underlying experiments require individual appraisal.
Limitations & review scope
- Source-linked does not mean a completed risk-of-bias review.
- A review is not an independent clinical replication; proposed mechanisms do not establish efficacy or safety.
Source checked 2026-09-27. This is a source-linked record, not a completed evidence review.